Ilaris

— THERAPEUTIC DISORDERS TREATED —
  • Arthritis/rheumatic disorders
  • Miscellaneous immune disorders

Ilaris Generic Name & Formulations

General Description

Canakinumab 150mg/mL soln for SC inj; 150mg/vial lyophilized pwd for SC inj after reconstitution; preservative-free.

Pharmacological Class

Interleukin-1beta blocker.

How Supplied

Single-dose vial—1

Generic Availability

NO

Ilaris Indications

Indications

Active Still's disease, including adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA).

Ilaris Dosage and Administration

Adults and Children

<2yrs: not established. Avoid injecting into scar tissue. Give as SC inj every 4 weeks. ≥2yrs (≥7.5kg): 4mg/kg; max 300mg.

Ilaris Contraindications

Not Applicable

Ilaris Boxed Warnings

Not Applicable

Ilaris Warnings/Precautions

Warnings/Precautions

Do not start in patients with active infection; discontinue if serious infection develops. History of recurring infections or conditions that predispose to infection. Test for and treat TB before starting therapy. Discontinue if severe hypersensitivity reaction occurs. Patients should receive all recommended vaccines (eg, pneumococcal, influenza) prior to initiating therapy. Macrophage activation syndrome (esp. in Still's disease). Pregnancy. Nursing mothers.

Ilaris Pharmacokinetics

See Literature

Ilaris Interactions

Interactions

Concomitant TNF inhibitors, other IL-1 blockers, live vaccines: not recommended. Monitor warfarin, other agents with narrow therapeutic indexes; may need dose adjustments.

Ilaris Adverse Reactions

Adverse Reactions

Nasopharyngitis, diarrhea, influenza, rhinitis, nausea, headache, bronchitis, gastroenteritis, pharyngitis, inj site reactions, weight increased, musculoskeletal pain, vertigo, abdominal pain; increased risk of infections, malignancies.

Ilaris Clinical Trials

See Literature

Ilaris Note

Not Applicable

Ilaris Patient Counseling

See Literature

Ilaris Generic Name & Formulations

General Description

Canakinumab 150mg/mL soln for SC inj; 150mg/vial lyophilized pwd for SC inj after reconstitution; preservative-free.

Pharmacological Class

Interleukin-1beta blocker.

How Supplied

Single-dose vial—1

Generic Availability

NO

Ilaris Indications

Indications

Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children ≥4yrs of age including: Familial Cold Autoinflammatory Syndrome (FCAS); Muckle-Wells Syndrome (MWS). Treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), and Familial Mediterranean Fever (FMF) in adults and children.

Ilaris Dosage and Administration

Adults and Children

Avoid injecting into scar tissue. CAPS: Give as SC inj every 8 weeks. <4yrs: not established. ≥4yrs: (≥15–≤40kg): 2mg/kg; children (15–40kg) with inadequate response: may increase to 3mg/kg; (>40kg): 150mg. TRAPS, HIDS/MKD, FMF: Give as SC inj every 4 weeks. <2yrs: not recommended. ≥2yrs: (≤40kg): 2mg/kg, may increase to 4mg/kg every 4 weeks if inadequate response; (>40kg): 150mg, may increase to 300mg every 4 weeks if inadequate response.

Ilaris Contraindications

Not Applicable

Ilaris Boxed Warnings

Not Applicable

Ilaris Warnings/Precautions

Warnings/Precautions

Do not start in patients with active infection; discontinue if serious infection develops. History of recurring infections or conditions that predispose to infection. Test for and treat TB before starting therapy. Discontinue if severe hypersensitivity reaction occurs. Patients should receive all recommended vaccines (eg, pneumococcal, influenza) prior to initiating therapy. Macrophage activation syndrome (esp. in Still's disease). Pregnancy. Nursing mothers.

Ilaris Pharmacokinetics

See Literature

Ilaris Interactions

Interactions

Concomitant TNF inhibitors, other IL-1 blockers, live vaccines: not recommended. Monitor warfarin, other agents with narrow therapeutic indexes; may need dose adjustments.

Ilaris Adverse Reactions

Adverse Reactions

Nasopharyngitis, diarrhea, influenza, rhinitis, nausea, headache, bronchitis, gastroenteritis, pharyngitis, inj site reactions, weight increased, musculoskeletal pain, vertigo, abdominal pain; increased risk of infections, malignancies.

Ilaris Clinical Trials

See Literature

Ilaris Note

Not Applicable

Ilaris Patient Counseling

See Literature